Expression of the Major Core Structural Protein (VP7) of Bluetongue Virus, by a Recombinant Capripox Virus, Provides Partial Protection of Sheep against a Virulent Heterotypic Bluetongue Virus Challenge

• Published in: Virology (New York, N.Y.) Vol. 220; no. 1; pp. 227 - 231
• Main Authors: WADE-EVANS, A.M., ROMERO, C.H., MELLOR, P., TAKAMATSU, H., ANDERSON, J., THEVASAGAYAM, J., FLEMING, M.J., MERTENS, P.P.C., BLACK, D.N.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-1996
• Subjects: Animals; Antibodies, Viral - blood; Bluetongue - prevention & control; bluetongue virus; Bluetongue virus - immunology; Capripoxvirus - genetics; Gene Expression; poxvirus; Sheep; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; Viral Core Proteins - genetics; Viral Core Proteins - immunology; Viral Vaccines - genetics; Viral Vaccines - immunology; Virulence
• ISSN: 0042-6822; 1096-0341
• DOI: 10.1006/viro.1996.0306

A recombinant capripox virus was constructed containing a cDNA copy of genome segment 7 of bluetongue virus (BTV) serotype 1 from South Africa (BTV 1SA), which expressed high levels of the major BTV core protein VP7 in infected lamb testis (LT) cells. Sheep vaccinated with this recombinant virus developed antibodies to VP7 (detected by ELISA) but no neutralizing antibodies to either the homologous or heterologous BTV serotype, prior to challenge (BTV 1 or BTV 3, respectively). Following challenge with a virulent heterotypic strain of BTV (BTV3 SA), all of the animals developed clinical signs of disease, indicating that they were infected and that the challenge virus did replicate. While all of the control animals died, six of the eight animals that were vaccinated with the recombinant capripox virus expressing VP7 recovered fully. This is the first report of a significant level of cross serotype protection against the lethal effects of a challenge with virulent BTV, produced by vaccination with a single BTV core protein, which did not generate a neutralizing antibody response.